Actin cytoskeletal inhibitor 19,20-epoxycytochalasin Q sensitizes yeast cells lacking ERG6 through actin-targeting and secondarily through disruption of lipid homeostasis

• Published in: Scientific reports Vol. 11; no. 1; pp. 7779 - 18
• Main Authors: Watchaputi, Kwanrutai, Somboon, Pichayada, Phromma-in, Nipatthra, Ratanakhanokchai, Khanok, Soontorngun, Nitnipa
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.04.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154; 631/208; 631/326; 631/337; 631/45; 631/61; 631/80; 631/92; Actin; Actins - antagonists & inhibitors; Antifungal agents; Antifungal Agents - pharmacology; Biopharmaceuticals; Biosynthesis; Cholesterol; Cytochalasins - pharmacology; Cytoskeleton; Drug resistance; Ergosterol; Fungicides; Homeostasis; Humanities and Social Sciences; Lipid Metabolism - drug effects; Lipids; Metabolic disorders; Methyltransferases - genetics; multidisciplinary; Saccharomyces cerevisiae - drug effects; Saccharomyces cerevisiae - genetics; Science; Science (multidisciplinary); Side effects; Toxins; Transcription; Tropical forests; Xylariales - metabolism; Yeast

Repetitive uses of antifungals result in a worldwide crisis of drug resistance; therefore, natural fungicides with minimal side-effects are currently sought after. This study aimed to investigate antifungal property of 19, 20-epoxycytochalasin Q (ECQ), derived from medicinal mushroom Xylaria sp. BCC...